UK Biosimulation Market (2026-2031)
The UK Biosimulation Market was valued at $57.9 Million in 2026 and projected to reach to $94.8 Million by 2031, representing a compound annual growth rate of 18.0%. The UK biosimulation market is positioned for sustained expansion driven by increasing adoption among pharmaceutical companies, contract research organizations, and academic institutions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
UK Biosimulation Market Trends and Insights
- The UK's advanced healthcare infrastructure and strong pharmaceutical research base are driving adoption of biosimulation technologies across drug development pipelines.
- UK-based organizations are increasingly leveraging computational modeling to accelerate clinical trial timelines and reduce development costs, positioning the UK as a key hub for biosimulation innovation in Europe. The UK market's 18.0% compound annual growth rate significantly outpaces global trends, reflecting the region's commitment to precision medicine and regulatory modernization.
- By 2031, the UK biosimulation market is expected to capture substantial value as healthcare providers and biotech firms integrate simulation platforms into their R&D workflows.
- The UK's regulatory environment and investment in life sciences infrastructure continue to support market expansion throughout the forecast period..
Key Market Statistics
- CAGR (2026-2031) 18.0% CAGR
- Market Size, 2026 ~USD 57.9 Million
- Forecast, 2031 ~USD 94.8 Million
- Country UK
UK Biosimulation Market Overview
Market Valuation Growth :
The UK biosimulation market is valued at $57.9 million in 2026 and is projected to reach $94.8 million by 2031, representing a robust 18% CAGR over the forecast period.
Advanced Healthcare Infrastructure :
The UK's world-class healthcare system and NHS framework provide an ideal environment for biosimulation adoption, with strong regulatory support from the MHRA and EMA.
Pharmaceutical Research Leadership :
The UK hosts major pharmaceutical and biotech companies leveraging computational modeling to accelerate drug development, reduce clinical trial costs, and improve time-to-market.
Outpacing Global Growth :
At 18% CAGR, the UK market is growing faster than the global biosimulation market at 16.7%, indicating strong regional demand and investment in computational drug development technologies.
UK Biosimulation Market Dynamics
- The UK's regulatory environment, combined with significant R&D investments and a skilled workforce in computational sciences, creates favorable conditions for market growth.
- Biosimulation technologies are becoming integral to drug development strategies, enabling organizations to optimize clinical trial designs and reduce development timelines.
- The market will benefit from growing partnerships between UK-based biotech firms and global pharmaceutical leaders seeking advanced modeling capabilities..
Related Ecosystem
Healthcare It
- Computed Tomography (CT)
- Machine Learning
- Magnetic Resonance Imaging (MRI)
- Natural Language Processing (NLP)
- Predictive Analytics
- CERNER CORPORATION
- PHILIPS HEALTHCARE
- Oracle Corporation
- GE HealthCare Technologies Inc.
- Siemens healthineers
Key Takeaways
- The UK biosimulation market is valued at $57.9 million in 2026 and will reach $94.8 million by 2031, representing an 18.0% CAGR.
- The UK's growth rate outpaces the global average, driven by advanced healthcare infrastructure and strong pharmaceutical R&D capabilities.
- UK organizations are adopting biosimulation to accelerate drug development, reduce clinical trial costs, and support precision medicine initiatives.
- The UK's regulatory environment and life sciences investment position it as a leading European hub for biosimulation innovation through 2031.
Biosimulation Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | INDIA (Application) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 16.7% from 2026 to 2031 |
| Largest Segment | CONSULTING & ADVISORY (Offering) |
| Market Size Base Year (Billions) | ~USD 4.27 (2026) |
| Revenue Forecast (Billions) | ~USD 9.24 (2031) |
| Segments Covered | Type, Application, Therapeutic Area, Revenue Model, Deployment Model, End User, Offering |
UK Biosimulation Market Report Segmentation
7 segment dimensions are covered across the global market.
By Type
- Adme/Toxicology
- Clinical Trial Simulation Software
- Clinical Trials
- Consulting & Advisory
- Data Analysis & Interpretation
- Demand Forecasting & Inventory Management
- Implementation, Training, And Support
- Integrated Software Suites/Platforms
- Lead Identification & Optimization
- Molecular Modeling & Simulation Software
- Other Biosimulation Software
- Other Manufacturing & Supply Chain Management Applications
- Pbpk Modeling & Simulation Software
- Phase I
- Phase Ii
- Phase Iii
- Phase Iv/Post-Marketing Surveillance
- Pk/Pd
- Pk/Pd Modeling & Simulation Software
- Preclinical Testing
- Production Planning & Optimization
- Quality Control & Process Monitoring
- Risk Management & Contingency Planning
- Standalone Modules
- Target Identification & Validation
- Toxicity Prediction Software
By Application
- Disease Modeling
- Drug Development
- Drug Discovery
- Manufacturing & Supply Chain Management
- Other Applications
By Therapeutic Area
- Cardiovascular Diseases
- Infectious Diseases
- Neurological Disorders
- Oncology
- Other Therapeutic Areas
By Revenue Model
- License-Based Models
- Pay-Per-Use Models
- Service-Based Models
- Subscription-Based Models
By Deployment Model
- Cloud-Based Models
- Hybrid Models
- On-Premise Models
By End User
- Academic & Research Institutions
- Contract Research Organizations
- Other End Users
- Pharmaceutical & Biotechnology Companies
- Regulatory Bodies
By Offering
- Services
- Software
Target Audience
- UK Pharmaceutical Companies : Major pharma and biotech firms in the UK need market intelligence to optimize biosimulation investments, benchmark against competitors, and accelerate drug development timelines.
- Contract Research Organizations (CROs) : UK-based CROs require detailed market data to expand biosimulation service offerings, identify client demand, and position themselves competitively in the growing computational modeling space.
- Healthcare Technology Investors : Private equity and venture capital firms investing in UK healthcare tech need market sizing and growth projections to evaluate biosimulation companies and funding opportunities.
- Academic & Research Institutions : UK universities and research centers need market insights to justify biosimulation infrastructure investments, secure funding, and establish industry partnerships.
- Healthcare Policy & Regulatory Bodies : NHS, MHRA, and government agencies require market data to inform policy decisions, support innovation initiatives, and understand adoption trends in computational drug development.
Key Companies in the UK Biosimulation Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| SANOFI | France | Public Company | Pediatric and combination vaccines (polio, pertussis, Hib, hexavalent),Other vaccines (RSV, hepatitis A, typhoid, yellow fever, rabies),Immunology and inflammation therapies, |
| CERTARA | United States | Public Company | Biosimulation platforms (Simcyp, Phoenix, NLME, Pirana),Regulatory data and submission software (Pinnacle 21, GlobalSubmit, CoAuthor, Metadata Repository),Discovery and informatics solutions (Chemaxon suite, D360, design tools), |
| DASSAULT SYSTÈMES | France | Public Company | 3D Modeling (CATIA, SOLIDWORKS, GEOVIA, BIOVIA),PLM & Collaboration (ENOVIA, CENTRIC PLM, 3DEXCITE, 3DEXPERIENCE collaboration),Simulation & Manufacturing (SIMULIA, DELMIA, 3DVIA), |
| SCHRöDINGER, INC. | United States | Public Company | Software,Drug Discovery – Collaborations (e.g., Novartis),Drug Discovery – Internal Pipeline, |
| SIMULATIONS PLUS | United States | Public Company | PBPK/PKPD and biopharmaceutics software (GastroPlus, DDDPlus, MembranePlus),QSP and disease-systems platforms (DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, Thales),ADMET Predictor, MedChem Designer and discovery-oriented AI/ML tools, |
| PHYSIOMICS PLC | United Kingdom | Public Company | Oncology modeling & simulation (Virtual Tumour–centric consulting),Broader quantitative pharmacology & computational biology services,Personalized medicine technology and related analytics, |
| INSTEM PLC | United Kingdom | Private Company | Research study management software (discovery, preclinical, early clinical),Regulatory submission and SEND-compliant dataset solutions,In silico and data insights / predictive analytics, |
SANOFI
Sanofi is a French multinational pharmaceutical company founded in 1994 with 74,846 employees. As a public company, it operates globally in the development, manufacturing, and distribution of medicines and vaccines.
CERTARA
Certara is a United States-based public company founded in 2008 with 1,546 employees. It provides software and services for drug development, including modeling, simulation, and regulatory consulting.
DASSAULT SYSTÈMES
Dassault Systèmes is a French software company founded in 1981 with 25,724 employees. As a public company, it develops 3D design, simulation, and digital lifecycle management solutions for various industries.
SCHRöDINGER, INC.
Schrödinger, Inc. is a United States-based public company founded in 1990 with 850 employees. It provides computational chemistry and molecular simulation software platforms for drug discovery and materials science.
SIMULATIONS PLUS
Simulations Plus is a United States-based public company founded in 1996 with 213 employees. It develops software for drug development, including pharmacokinetic and pharmacodynamic modeling and simulation.
PHYSIOMICS PLC
Physiomics PLC is a United Kingdom-based public company founded in 2001 with 10 employees. It specializes in computational biology and systems pharmacology for drug development.
INSTEM PLC
Instem PLC is a United Kingdom-based private company founded in 1969 with 510 employees. It provides software and services for data management and analysis in preclinical and clinical research.
Reasons to Buy this Report
- UK-Specific Market Sizing : Obtain precise valuation data for the UK biosimulation market with detailed forecasts through 2031, enabling accurate budget allocation and investment planning for UK operations.
- Competitive Landscape Intelligence : Understand the competitive positioning of UK-based and international biosimulation providers operating in the British market, identifying partnership and acquisition opportunities.
- Regulatory & Compliance Insights : Gain clarity on UK-specific regulatory requirements, MHRA guidelines, and post-Brexit considerations affecting biosimulation adoption in pharmaceutical development.
- Growth Driver Analysis : Identify key factors driving the 18% CAGR in the UK market, including NHS adoption, academic partnerships, and pharmaceutical R&D investments specific to the region.
- Strategic Market Entry : Develop informed market entry strategies for UK expansion with data on customer segments, adoption rates, and investment priorities among UK pharmaceutical and biotech organizations.
Frequently asked questions
What is the current size of the UK biosimulation market?
The UK biosimulation market is valued at $57.9 million in 2026 and is projected to grow to $94.8 million by 2031.
What is the growth rate of the UK biosimulation market?
The UK biosimulation market is growing at a compound annual growth rate (CAGR) of 18.0% from 2026 to 2031.
Why is the UK biosimulation market growing faster than the global average?
The UK's advanced healthcare infrastructure, strong pharmaceutical research base, supportive regulatory environment, and significant life sciences investment drive faster adoption of biosimulation technologies compared to global trends.
What are the primary drivers of biosimulation adoption in the UK?
Key drivers include the need to accelerate drug development timelines, reduce clinical trial costs, support precision medicine initiatives, and leverage computational modeling in R&D workflows across UK pharmaceutical and biotech organizations.
How does the UK biosimulation market compare to other European markets?
The UK's 18.0% CAGR and strong life sciences ecosystem position it as a leading European hub for biosimulation innovation, with significant investment in regulatory modernization and precision medicine capabilities.
RESEARCH METHODOLOGY
This research study involved the extensive use of both primary and secondary sources. It involved the analysis of various factors affecting the industry to identify the segmentation types, industry trends, key players, the competitive landscape of market players, and key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies.
Secondary Research
This research study extensively utilized secondary sources, including directories, databases such as Dun & Bradstreet, Bloomberg Businessweek, and Factiva, as well as white papers, annual reports, and companies' house documents. The secondary research aimed to gather and analyze information for a comprehensive and commercially focused study of the biosimulation market, encompassing technical aspects and market dynamics. It also facilitated the identification of key players, market classification, industry trends, geographical markets, and significant market-related developments. Additionally, a database of prominent industry leaders was compiled through secondary research.
Primary Research
In the primary research process, various supply-side and demand-side sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side included industry experts such as CEOs, vice presidents, marketing and sales directors, technology & innovation directors, engineers, and related key executives from various companies and organizations operating in the biosimulation market. Primary sources from the demand side included personnel from pharmaceutical & biotechnology companies, contract research organizations, academic & research institutes, and regulatory bodies.
A breakdown of the primary respondents is provided below:
Note: Tiers are defined based on a company’s total revenue, as of 2025: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million. Other designations include sales managers, marketing managers, and product managers.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biosimulation market was determined after data triangulation through the two approaches mentioned below. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach.
Biosimulation Market : Top-Down and Bottom-Up Approach
Data Triangulation
The size of the biosimulation market was estimated through segmental extrapolation using the bottom-up approach. The methodology used is as follows: -
- Revenues for individual companies were gathered from public sources and databases.
- Shares of leading players in the biosimulation market were gathered from secondary sources to the extent available. In certain cases, shares of biosimulation businesses were ascertained after a detailed analysis of various parameters, including product portfolios, market positioning, selling price, and geographic reach & strength.
- Individual shares or revenue estimates were validated through interviews with experts.
- The total revenue in the biosimulation market was determined by extrapolating the market share data of major companies.
Market Definition
Biosimulation is a technology that employs computer-aided simulations to replicate and predict the dynamics of biological processes and systems. It uses modern computational power to analyze and model biological behavior through mathematical expressions. Biosimulation, often referred to as Computer-aided Drug Design (CADD), plays a critical role in various stages of drug discovery and development. Leveraging AI and machine learning, biosimulation enhances the evaluation of drug safety, efficacy, and interactions, ultimately streamlining clinical trial design and accelerating time-to-market for new therapeutics.
Key Stakeholders
- Clinical/Physician centers
- Biosimulation vendors
- Clinical research organizations
- Pharmaceutical/Biopharmaceutical companies
- Research & development (R&D) companies
- Business research and consulting service providers
- Medical research laboratories
- Academic medical centers/Universities/Hospitals
- Regulatory agencies
- Clinical researchers
- Accountable care organizations
- Investors and venture capitalists
Report Objectives
- To define, describe, and forecast the biosimulation market based on offering, phase of development, modality, application, therapeutic area, deployment mode, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall biosimulation market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments such as product launches & approvals, partnerships, agreements, and collaborations in the overall biosimulation market
- To benchmark players within the market using the proprietary "Competitive Leadership Mapping" framework, which analyzes market players on various parameters within the broad categories of business and product strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:
- Company information
- Detailed analysis and profiling of additional market players (up to 5)
Regional Analysis
- Further breakdown of the Rest of Asia Pacific biosimulation market into Taiwan, New Zealand, Thailand, Singapore, Malaysia, and other countries
- Further breakdown of the Rest of Europe biosimulation market into Russia, Austria, Finland, Sweden, Turkey, Norway, Poland, Portugal, Romania, Denmark, and other countries
Get the Full Biosimulation Market Report
Full forecast, segment splits, and company analysis for all Biosimulation Market.
- US Biosimulation Market
- Canada Biosimulation Market
- Germany Biosimulation Market
- France Biosimulation Market
- Italy Biosimulation Market
- Spain Biosimulation Market
- China Biosimulation Market
- Japan Biosimulation Market
- India Biosimulation Market
- Australia Biosimulation Market
- South Korea Biosimulation Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report